INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
发明人:
CHO, WON JEAKR,조원제
申请号：
KR1020140124591
公开号：
KR1020160033536A
申请日:
2014.09.18
申请国别(地区):
KR
年份:
2016
代理人:
摘要：
The present invention relates to a novel heteroarylisoquinoline-based derivative and salt thereof. The heteroarylisoquinoline-based derivative compound of the present invention has an apoptosis effect against cancer cells, and has toxicity significantly lower than toxicity of doxorubicin (DOX), which is an existing cancer treatment agent, with respect to normal cells. The heteroarylisoquinoline-based derivative compound of the present invention has an excellent cytotoxicity against cancer cells and excellent inhibitory activity against topoisomerases (topos). In addition, the heteroarylisoquinoline-based derivative compound an inhibitory concentration (IC50) against cancer cells compared to an existing anticancer agent and thus can exhibit the cytotoxicity effect against cancer cells with only a small amount of injection. In particular, the compound of the present invention has the excellent cytotoxicity against cancers cells of breast cancer or colon cancer among various cancer cells.COPYRIGHT KIPO 2016본 발명은 신규한 헤테로아릴이소퀴놀린계 유도체(heteroarylisoquinoline derivatives) 및 그의 염에 관한 것이다. 본 발명의 헤테로아릴이소퀴놀린계 유도체 화합물은 암 세포에 대한 사멸(apoptosis) 효과가 있으며, 종래의 항암 치료제인 독소루비신(DOX)와 비교하여 정상 세포에 대한 독성이 현저히 낮다. 본 발명의 헤테로아릴이소퀴놀린계 유도체 화합물은 암 세포에 대한 세포독성(cytotoxicity) 효과 및 토포아이소머라아제(topoisomerases, topos)에 대한 억제 활성이 우수하다. 또한, 종래의 항암제와 비교하여 암세포에 대한 저해농도(IC50)가 낮아 저용량 투여만으로도 암세포에 대한 세포 독성 효과를 나타낼 수 있다는 장점이 있으며, 특히 본 발명의 화합물은 다양한 암세포 중 특히 유방암 또는 대장암에 대한 세포 독성 효과가 뛰어나다.
